Artelo Biosciences Will Present at BIO-Europe 2026
The company will showcase its fatty acid binding protein inhibitor program this November in Cologne.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Do clinical trial updates from pharmaceutical companies increase your trust in future medical treatment options?
Artelo Biosciences is scheduled to present on November 10, 2026, at the BIO-Europe 2026 conference in Cologne, Germany. This marks the first selection of the clinical-stage firm to present at the event, where it will outline its progress on ART26.12.
Why it matters
The appearance serves as a strategic effort to initiate business development discussions with potential partners in the pain and inflammation sectors. It highlights the company's progress in advancing its research toward larger industry partnerships.
Preclinical data for ART26.12 indicates reduced osteoarthritis-associated pain over a 4-week period. Furthermore, nonclinical study animals treated with the drug exhibited less stomach tissue damage compared to those treated with naproxen.
The players
Artelo Biosciences
A Solana Beach-based firm focusing on lipid-signaling modulation for pain and inflammation.
Andrew Yates
The company representative scheduled to deliver the presentation at BIO-Europe.
The details
ART26.12 is a designed inhibitor of fatty acid binding protein 5 (FABP5), a protein implicated in pain signaling pathways. By inhibiting this target, the molecule aims to modulate pain responses while avoiding the gastric side effects often associated with standard nonsteroidal anti-inflammatory drugs like naproxen. Phase 1 study data in healthy volunteers have demonstrated a favorable safety and tolerability profile for the compound.
Timeline
November 9-11, 2026: BIO-Europe 2026 conference.
November 10, 2026: Artelo company presentation at 4:15pm CET.
The Tech Race
The appearance builds upon the momentum established at the 2025 BIO-Europe conference, which facilitated 32,500 one-to-one partnering meetings among 3,252 participating companies. Artelo is now leveraging this network to transition from early research to industry-wide partnership exploration.
The presentation provides a public update on the status of the ART26.12 program for industry stakeholders and investors. Clinical and research progress remain in the research-stage, with future availability dependent on the outcome of development partnerships and further trials.
The takeaway
The presentation confirms that Artelo is moving its FABP5 inhibitor closer to a formal partnering phase. Observers should track the outcome of the business development meetings held during the conference to determine if the firm secures the collaboration necessary for further clinical advancement.
Further reading
For more on industry developments, see our coverage in Biotech.
Live Poll
Do clinical trial updates from pharmaceutical companies increase your trust in future medical treatment options?
